Xcela Power Injectable PICC Maximal Barrier Nursing Kit The Maximal Barrier Nursing Kits are Tan...
FDA Device Recall #Z-0708-2017 — Class II — August 29, 2016
Recall Summary
| Recall Number | Z-0708-2017 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 29, 2016 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Angiodynamics Inc. (Navilyst Medical Inc.) |
| Location | Glens Falls, NY |
| Product Type | Devices |
| Quantity | 75 packages (boxes of 5) |
Product Description
Xcela Power Injectable PICC Maximal Barrier Nursing Kit The Maximal Barrier Nursing Kits are Tandem Pack Convenience Kits packaged with a NMI PICC and accessories. The Xcela Power Injectable PICC is indicated for short or long-term peripheral access to the central venous system for intravenous therapy, including but not limited to, the administration of fluids, medications and nutrients; the sampling of blood; and for power injection of contrast media
Reason for Recall
Medline Industries, Inc. supplies Navilyst with sterile package gloves included in the tandem packing of the Maximal Barrier Nursing Kits. Medline has determined that specific lots of the gloves supplied to Navilyst contain an incorrect expiration date. Navilyst has confirmed that Medlines affected sterile gloves (Medline Part Number MSG1075/MSG3075) have been included in a limited number of kits.
Distribution Pattern
Nationwide Distribution including AZ, CA, FL, GA, HI, IL< IN< KS, LA, MI, MN, MO, ND, NM, OH, OR, PA, TN, TX, WA & the District of Columbia.
Lot / Code Information
Batch/Lot: 505722, 5056512
Other Recalls from Angiodynamics Inc. (Navilyst Medical ...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1467-2021 | Class II | AngioDynamics Safe Sheath Ultralite - Vascular ... | Feb 22, 2021 |
| Z-1466-2021 | Class II | Smart Port CT-Implantable Port Catalogue #: CT9... | Feb 22, 2021 |
| Z-0411-2020 | Class II | Starburst Talon Semi-Flex Electrosurgical Devic... | Oct 2, 2019 |
| Z-0504-2020 | Class II | BIOFLO 8F SINGLE PLASTIC FILLED; VALVED, UPN H9... | Sep 18, 2019 |
| Z-0501-2020 | Class II | BIOFLO 8F SINGLE PLASTIC FILLED; NON-VALVED, UP... | Sep 18, 2019 |
Frequently Asked Questions
Sterility recalls for medical devices vary in severity. If you have already had a procedure using a potentially non-sterile device, contact your healthcare provider immediately — you may need monitoring for signs of infection. Symptoms to watch for include fever, redness or swelling at the surgical site, unusual pain, or discharge. For devices that have not yet been used, they should be quarantined and returned to the manufacturer per the recall notice. Non-sterile implants can cause serious infections; early detection and treatment are critical.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.